Drugs / Eptocag alfa, activated
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT04789954 | Dec 2020 → Aug 2021 | hemophilia A, hemophilia B | AryoGen Pharmed Co. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Eptocag alfa, activated | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04789954 ↗ |
| Modality | Protein / enzyme biologic | “recombinant human FVII activated” NCT04789954 ↗ |
| Route | Intravenous | “Single dose, intravenously” NCT04789954 ↗ |